Hospital
Southern Regional Medical Corporation
Southern Regional Medical Corporation was paid $31.59M by Medicaid between Jan 2018 and Dec 2024, across 333 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoSOUTHERN REGIONAL MEDICAL CORPORATION
HOUMA, LA 70363
HOUMA, LA 70363
33aNPI1326485749assigned 05/24/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.59M
24GClaims1,270,666
24DCodes billed333
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#12 of 96
Median peer was paid$5.17M
This provider vs. median6.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 187,623 | $4.06M | |
| 2019 | 197,899 | $4.45M | |
| 2020 | 146,755 | $3.30M | |
| 2021 | 175,208 | $4.55M | |
| 2022 | 199,324 | $5.18M | |
| 2023 | 204,578 | $5.65M | |
| 2024incomplete | 159,279 | $4.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 45,418 | 42,383 | $5.20M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 16% | 174,444 | 156,633 | $5.02M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 117,382 | 105,654 | $3.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.3% | 33,638 | 31,786 | $2.62M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 16,009 | 14,628 | $2.55M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.8% | 14,727 | 13,468 | $892K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 18,864 | 17,530 | $763K |
| 80053 | Comprehensive metabolic panel | 2.4% | 93,821 | 80,822 | $762K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 4,888 | 2,651 | $521K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 84,107 | 71,216 | $479K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 22,528 | 18,157 | $347K |
| 80061 | Lipid panel | 1.1% | 30,353 | 28,795 | $335K |
321 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 978 | $296K |
| 20610 | <1% | 2,479 | $287K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,337 | $285K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,308 | $260K |
| 36415 | Collection of venous blood by venipuncture | <1% | 111,336 | $250K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,196 | $239K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,202 | $239K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29,831 | $236K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,530 | $230K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,085 | $226K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,996 | $205K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,466 | $202K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,459 | $184K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,758 | $181K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 805 | $173K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,106 | $169K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,570 | $136K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,711 | $127K |
| 87536 | <1% | 1,955 | $124K | |
| 90686 | <1% | 10,443 | $123K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,851 | $119K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,862 | $117K |
| 80050 | General health panel | <1% | 3,043 | $115K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,884 | $115K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,068 | $113K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 549 | $111K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,293 | $101K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 728 | $100K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 350 | $98K |
| 81025 | <1% | 14,564 | $95K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 184 | $89K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,007 | $88K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,761 | $87K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,763 | $82K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,133 | $81K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,674 | $69K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 391 | $67K |
| G0378 | Hospital observation service, per hour | <1% | 1,218 | $66K |
| 51798 | <1% | 2,251 | $64K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 798 | $62K |
| 96367 | <1% | 2,463 | $61K | |
| 97597 | <1% | 1,406 | $59K | |
| 52000 | <1% | 299 | $58K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 960 | $58K |
| 84484 | <1% | 7,190 | $55K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 80 | $53K |
| 83880 | <1% | 2,325 | $52K | |
| 81001 | <1% | 21,417 | $51K | |
| J3490 | Unclassified drugs | <1% | 2,048 | $46K |
| 83735 | <1% | 9,562 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,981 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,284 | $44K |
| 90671 | <1% | 514 | $41K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 807 | $40K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 128 | $40K |
| 86361 | <1% | 1,917 | $39K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,968 | $37K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 239 | $36K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 371 | $32K |
| 74018 | <1% | 1,059 | $32K | |
| 84100 | <1% | 9,405 | $31K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,071 | $31K |
| 81514 | <1% | 228 | $31K | |
| 86160 | <1% | 3,852 | $31K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,551 | $30K |
| 83970 | <1% | 1,053 | $30K | |
| 92134 | <1% | 2,379 | $29K | |
| 71250 | <1% | 347 | $28K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,194 | $27K |
| 77077 | <1% | 492 | $27K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,231 | $27K |
| 80074 | <1% | 585 | $25K | |
| 96417 | <1% | 513 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,513 | $24K |
| 93351 | <1% | 87 | $22K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 63 | $21K |
| 73110 | <1% | 657 | $21K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 70 | $21K |
| 0002A | <1% | 578 | $21K | |
| 87522 | Neg quan hep c or qual rna | <1% | 507 | $20K |
| 43235 | <1% | 181 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 666 | $19K |
| 95886 | <1% | 459 | $19K | |
| 94060 | <1% | 361 | $18K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 60 | $18K |
| 87634 | <1% | 292 | $18K | |
| 0001A | <1% | 584 | $18K | |
| 83690 | <1% | 3,432 | $18K | |
| 86225 | <1% | 1,692 | $17K | |
| 82570 | <1% | 4,348 | $17K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 579 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,407 | $17K |
| 86703 | <1% | 1,521 | $17K | |
| 73130 | <1% | 515 | $16K | |
| 81596 | <1% | 457 | $16K | |
| 84439 | <1% | 2,002 | $16K | |
| 86140 | <1% | 4,051 | $16K | |
| 64721 | <1% | 69 | $14K | |
| 73610 | <1% | 485 | $14K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 138 | $14K |
| 81002 | <1% | 6,692 | $13K | |
| 73564 | <1% | 369 | $13K | |
| 94664 | <1% | 831 | $13K | |
| 90732 | <1% | 306 | $13K | |
| 80069 | <1% | 2,109 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 378 | $12K |
| 82607 | <1% | 1,013 | $12K | |
| 86803 | <1% | 975 | $12K | |
| 82043 | <1% | 2,525 | $12K | |
| 82728 | <1% | 1,192 | $12K | |
| 82105 | <1% | 1,010 | $11K | |
| 95012 | <1% | 629 | $11K | |
| 70355 | <1% | 421 | $11K | |
| 84153 | <1% | 757 | $11K | |
| 84466 | <1% | 1,101 | $10K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 44 | $10K |
| 85610 | <1% | 3,507 | $10K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,448 | $10K |
| 81003 | <1% | 5,615 | $10K | |
| 94760 | <1% | 7,642 | $9K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 260 | $9K |
| 85027 | <1% | 1,701 | $9K | |
| 86200 | <1% | 824 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 437 | $9K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,618 | $9K |
| 90715 | <1% | 291 | $8K | |
| 84550 | <1% | 2,248 | $8K | |
| 73630 | <1% | 252 | $8K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 240 | $8K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 67 | $8K |
| 76942 | <1% | 421 | $7K | |
| 20552 | <1% | 159 | $7K | |
| 85651 | <1% | 2,185 | $7K | |
| 86592 | <1% | 1,963 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,327 | $7K |
| 96415 | <1% | 315 | $7K | |
| 93356 | <1% | 64 | $6K | |
| 92133 | <1% | 344 | $6K | |
| 64447 | <1% | 168 | $6K | |
| 87210 | <1% | 1,309 | $6K | |
| 86038 | <1% | 569 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 391 | $6K |
| 97165 | <1% | 101 | $6K | |
| 83605 | <1% | 747 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,510 | $5K |
| 64445 | <1% | 61 | $5K | |
| 83540 | <1% | 1,100 | $5K | |
| 90677 | <1% | 149 | $5K | |
| 73562 | <1% | 199 | $5K | |
| 0004A | <1% | 121 | $5K | |
| 97161 | <1% | 95 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,064 | $5K |
| 82962 | <1% | 2,175 | $4K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,398 | $4K |
| 85652 | <1% | 2,118 | $4K | |
| 84156 | <1% | 1,549 | $4K | |
| 72100 | <1% | 150 | $4K | |
| 83516 | <1% | 437 | $4K | |
| 73521 | <1% | 63 | $4K | |
| 90656 | <1% | 1,009 | $4K | |
| 86431 | <1% | 750 | $3K | |
| 29075 | <1% | 31 | $3K | |
| 76642 | <1% | 56 | $3K | |
| 80076 | <1% | 468 | $3K | |
| 67228 | <1% | 15 | $3K | |
| 95908 | <1% | 71 | $3K | |
| 92083 | <1% | 148 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 590 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,639 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,157 | $3K |
| 80320 | <1% | 405 | $3K | |
| 90714 | <1% | 201 | $3K | |
| 80361 | <1% | 423 | $3K | |
| 80365 | <1% | 422 | $3K | |
| 94618 | <1% | 27 | $3K | |
| 94667 | <1% | 132 | $2K | |
| 97166 | <1% | 49 | $2K | |
| 82565 | <1% | 630 | $2K | |
| 64612 | <1% | 32 | $2K | |
| 83010 | <1% | 203 | $2K | |
| 86235 | <1% | 126 | $2K | |
| 95910 | <1% | 51 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,115 | $2K |
| 64415 | <1% | 124 | $2K | |
| 73560 | <1% | 78 | $2K | |
| 91200 | <1% | 34 | $2K | |
| 0054A | <1% | 57 | $2K | |
| 85730 | <1% | 434 | $2K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 30 | $2K |
| 86147 | <1% | 156 | $2K | |
| 88112 | <1% | 41 | $2K | |
| 87081 | <1% | 235 | $2K | |
| 84520 | <1% | 634 | $2K | |
| 94729 | <1% | 67 | $2K | |
| 86480 | <1% | 26 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 47 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 407 | $2K |
| 73030 | <1% | 65 | $2K | |
| 27096 | <1% | 52 | $2K | |
| 87088 | <1% | 292 | $2K | |
| 94727 | <1% | 68 | $1K | |
| 82977 | <1% | 207 | $1K | |
| 94150 | <1% | 54 | $1K | |
| 87040 | <1% | 182 | $1K | |
| 82550 | <1% | 241 | $1K | |
| 51741 | <1% | 55 | $1K | |
| 87481 | <1% | 20 | $1K | |
| 93320 | <1% | 38 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,136 | $1K |
| 87807 | <1% | 103 | $1K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 32 | $1K |
| 87186 | <1% | 217 | $1K | |
| 94761 | <1% | 537 | $1K | |
| 0003A | <1% | 28 | $1K | |
| 87077 | <1% | 216 | $1K | |
| 82784 | <1% | 128 | $1K | |
| 93325 | <1% | 38 | $1K | |
| 84460 | <1% | 256 | $1K | |
| 86146 | <1% | 130 | $954.00 | |
| 72200 | <1% | 29 | $890.74 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 665 | $884.23 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,647 | $857.50 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 300 | $849.92 |
| 83520 | <1% | 24 | $830.67 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,240 | $829.28 |
| 83883 | <1% | 203 | $807.79 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $800.96 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 16 | $799.83 |
| 0053A | <1% | 30 | $785.60 | |
| 0031A | <1% | 29 | $778.49 | |
| 91322 | <1% | 13 | $766.46 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 322 | $748.48 |
| 84450 | <1% | 178 | $730.96 | |
| 82378 | <1% | 64 | $728.62 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 253 | $725.62 |
| 83655 | <1% | 60 | $722.68 | |
| 97802 | <1% | 55 | $709.96 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 161 | $709.50 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 147 | $626.08 |
| V2632 | Posterior chamber intraocular lens | <1% | 66 | $591.68 |
| 97164 | <1% | 15 | $555.69 | |
| 85613 | <1% | 68 | $548.38 | |
| 0052A | <1% | 30 | $530.68 | |
| 73502 | <1% | 19 | $523.50 | |
| 82247 | <1% | 152 | $516.21 | |
| 0071A | <1% | 13 | $508.37 | |
| 86769 | <1% | 15 | $507.99 | |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 293 | $501.83 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 404 | $496.57 |
| 86162 | <1% | 31 | $468.58 | |
| 86364 | <1% | 85 | $460.13 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 20 | $458.27 |
| 86593 | <1% | 142 | $455.54 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 17 | $405.00 |
| 93296 | <1% | 104 | $399.55 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 26 | $378.18 |
| 94010 | <1% | 13 | $374.24 | |
| 90746 | <1% | 12 | $360.22 | |
| 0352U | <1% | 83 | $320.79 | |
| 82248 | <1% | 63 | $293.07 | |
| 88342 | <1% | 798 | $272.84 | |
| 86039 | <1% | 24 | $224.52 | |
| 96523 | <1% | 13 | $214.10 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 76 | $213.86 |
| 90694 | <1% | 216 | $191.91 | |
| 86706 | <1% | 34 | $161.74 | |
| 86258 | <1% | 36 | $156.74 | |
| 84030 | <1% | 26 | $146.92 | |
| 00731 | <1% | 448 | $145.82 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 419 | $125.32 |
| G0127 | Trimming of dystrophic nails, any number | <1% | 13 | $118.75 |
| 82746 | <1% | 15 | $118.04 | |
| C1769 | Guide wire | <1% | 66 | $91.47 |
| 82040 | <1% | 31 | $79.50 | |
| 90480 | <1% | 13 | $59.16 | |
| 85045 | <1% | 17 | $56.22 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $53.06 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 57 | $44.22 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 63 | $43.97 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 19 | $38.28 |
| 85018 | <1% | 15 | $37.10 | |
| 85014 | <1% | 15 | $37.10 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 241 | $28.40 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 13 | $26.48 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 38 | $25.96 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 85 | $25.56 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 13 | $22.76 |
| 90662 | <1% | 161 | $22.44 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 314 | $20.08 |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | <1% | 86 | $18.46 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 24 | $9.32 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 27 | $9.23 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 15 | $2.64 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 36,361 | $0.00 |
| 00813 | 0% | 215 | $0.00 | |
| 88304 | 0% | 27 | $0.00 | |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 638 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 1,388 | $0.00 |
| 91305 | 0% | 111 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 12 | $0.00 |
| 91307 | 0% | 38 | $0.00 | |
| 80329 | 0% | 34 | $0.00 | |
| 00142 | 0% | 35 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 12 | $0.00 |
| 91303 | 0% | 27 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 19 | $0.00 |
| 00812 | 0% | 193 | $0.00 | |
| 82172 | 0% | 267 | $0.00 | |
| 80326 | 0% | 160 | $0.00 | |
| 80364 | 0% | 160 | $0.00 | |
| 01810 | 0% | 49 | $0.00 | |
| 00811 | 0% | 878 | $0.00 | |
| 80355 | 0% | 160 | $0.00 | |
| 91300 | 0% | 1,182 | $0.00 | |
| 80347 | 0% | 160 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 98 | $0.00 |
| C9447 | Injection, phenylephrine and ketorolac, 4 ml vial | 0% | 12 | $0.00 |
| 90653 | 0% | 45 | $0.00 | |
| 76000 | 0% | 16 | $0.00 | |
| J9035 | Injection, bevacizumab, 10 mg | 0% | 13 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEOPLES, PHYLLIS (PRESIDENT AND CEO)
Parent organizationSOUTHERN REGIONAL MEDICAL CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Gulf Coast Surgical Center LLC | Houma, LA | $142K |
| Physicians Medical Center, LLC | Houma, LA | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.